Drugs / Omidria
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Omidria | — | 2015-07-28 | europa.eu ↗ |
| Approved | US (FDA) | OMIDRIA | — | 2014-05-30 | fda.gov ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06681688 | Jul 2024 → Jun 2025 overdue | cataract | Inder Paul Singh, M.D. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omidria | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06681688 ↗ |
| Route | Other | “Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%” NCT06681688 ↗ |